InsidersTradesSigma
Track the Mirati Therapeutics, Inc. share price and the full management transaction log of the company, a listed equity based in United States. Shares are quoted on the US market, under the authority of SEC (Form 4). Operating in the Healthcare & Pharma sector, Mirati Therapeutics, Inc. has logged 115 reports. The latest transaction was reported on 25 January 2024 (Disposition). Among the most active insiders: Christensen Jamie. Every trade is free.
115
Insider Decl.
n/a
Thresholds
€3m
3 ops.
Buy Volume
€3m
44 ops.
Sell Volume
27Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 25 January 2024
Declarations115 total
287,866 sharesCommon StockSEC:0000895345-24-000019:0
8,717 sharesCommon StockSEC:0001140361-24-003533:0
20,425 sharesCommon StockSEC:0001140361-24-003528:2
675 sharesCommon StockSEC:0001140361-24-003540:0
6,021 sharesCommon StockSEC:0001140361-24-003535:0
43,073 sharesCommon StockSEC:0001140361-24-003538:0
4,162 sharesCommon StockSEC:0001140361-24-003537:0
10,547 sharesCommon StockSEC:0001140361-24-003530:0
7,555 sharesCommon StockSEC:0001140361-24-003527:0
6,021 sharesCommon StockSEC:0001140361-24-003534:0
27,801 sharesCommon StockSEC:0001140361-24-003531:0
56,495 sharesCommon StockSEC:0001140361-24-003529:0
4,444 sharesCommon StockSEC:0001140361-24-003536:0
6,021 sharesCommon StockSEC:0001140361-24-003539:0
123,389 sharesCommon StockSEC:0001140361-24-003528:0
94,057 sharesCommon StockSEC:0001140361-24-003528:1
1,302 sharesCommon StockSEC:0001140361-24-003532:0
966 shares@ US$59.022.1% of flowCommon StockSEC:0001628280-24-001696:0
966 shares@ US$59.021.8% of flowCommon StockSEC:0001628280-24-001690:0
2,090 shares@ US$58.924.4% of flowCommon StockSEC:0001628280-24-000977:0
1,531 shares@ US$58.812.8% of flowCommon StockSEC:0001628280-24-000699:0
17,021 shares@ US$58.7576.3% of flowCommon StockSEC:0001628280-24-000279:0
17,021 shares@ US$58.7530.8% of flowCommon StockSEC:0001628280-24-000288:0
6,808 shares@ US$58.75100.0% of flowCommon StockSEC:0001628280-24-000319:0
6,808 shares@ US$58.75100.0% of flowCommon StockSEC:0001628280-24-000357:0
25 of 115 declarations
关于 Mirati Therapeutics, Inc.
Mirati Therapeutics, Inc. (NASDAQ: MRTX) 是一家总部位于美国的生物制药公司，专注于精准肿瘤学。对于讲法语的投资者而言，它完全符合健康与制药行业，其研究驱动的特点集中于靶向癌症疗法和生物标志物引导的药物开发。该公司成立于 1995 年，历史总部位于美国加利福尼亚州圣迭戈。随着时间的推移，Mirati 围绕发现和开发针对基因定义癌症（特别是 KRAS 突变驱动的肿瘤）的疗法建立了其身份。当 Bristol Myers Squibb 宣布并随后于 2024 年完成对 Mirati 的收购时，其公司发展轨迹发生了实质性变化，这有效地结束了 Mirati 作为独立上市发行人的生命。（[news.bms.com](https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-Mirati-Therapeutics-Strengthening-and-Diversifying-Oncology-Portfolio/default.aspx?utm_source=openai)） Mirati 的主要资产是 KRAZATI (adagrasib)，一种靶向 KRAS G12C 抑制剂。该药物最初是为先前治疗过的 KRAS G12C 突变非小细胞肺癌开发的，其开发计划后来扩展到其他实体瘤，包括 KRAS G12C 突变结直肠癌。Bristol Myers Squibb 最近披露的（现在涵盖 Mirati 资产基础的）信息强调了 KRAZATI 的重要里程碑，包括积极的 KRYSTAL-12 3 期数据和 FDA 于 2024 年加速批准用于 KRAS G12C 突变结直肠癌。这些事件强化了 Mirati 核心平台的临床相关性，并验证了该公司的精准肿瘤学战略。（[investors.bms.com](https://investors.bms.com/iframes/press-releases/press-release-details/2024/Bristol-Myers-Squibb-Announces-U.S.-FDA-Accelerated-Approval-of-KRAZATI-adagrasib-in-Combination-with-Cetuximab-for-Adult-Patients-with-Previously-Treated-KRAS-G12C-Mutated-Locally-Advanced-or-Metastatic-Colorectal-Cancer-CRC/default.aspx?utm_source=openai)） 从竞争角度来看，Mirati 通过高度集中的肿瘤学特许经营权实现了差异化，该特许经营权建立在分子靶向和治疗服务不足的患者亚群的基础上。在生物制药领域，如果公司能够展示强大的临床疗效、可控的安全性以及清晰的监管途径，这种模式可以创造有吸引力的价值。在被收购之前，Mirati 与其他靶向肿瘤学开发商竞争，但随着 KRAZATI 进入后期开发并进入市场，其形象大幅提升。更广泛的管线还包括 KRAS 相关肿瘤学和其他肿瘤靶点的早期临床项目，这使得 Mirati 即使在主要商业产品之外也是一个有趣的创新资产。被 Bristol Myers Squibb 收购后，Mirati 不再作为独立的运营公司进行交易，但其科学和产品平台在更大的全球制药组织内部仍然具有战略重要性。（[news.bms.com](https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-Mirati-Therapeutics-Strengthening-and-Diversifying-Oncology-Portfolio/default.aspx?utm_source=openai)） 从地理上看，Mirati 的历史足迹集中在美国，其圣迭戈基地是研究和公司运营的中心。如今，与 Mirati 资产相关的任何商业和开发活动都位于 Bristol Myers Squibb 更广泛的全球基础设施内，而市场参考仍然是美国交易所背景，特别是 Mirati 之前的上市地 NASDAQ 和 Bristol Myers Squibb 的 NYSE。最近的主要发展包括收购完成、KRAZATI 整合到 Bristol Myers Squibb 的肿瘤学产品组合中，以及 2024 年该药物持续的临床和监管势头。（[news.bms.com](https://news.bms.com/news/corporate-financial/2024/Bristol-Myers-Squibb-Completes-Acquisition-of-Mirati-Therapeutics-Strengthening-and-Diversifying-Oncology-Portfolio/default.aspx?utm_source=openai)）
